---
type: llm
weight: 3
focus: { source: file, path: report.md }
---

Correct main recommendation: do NOT fund the national rollout (EUR 3,960,000 a year) on this evidence. Compared with the five similarly weak untreated regions and with click & collect removed, the pilot effect is about 1.4% (pilot clean growth 8.5% vs 7.0%), worth roughly EUR 82,493 of sales and EUR -246,953 of contribution after the EUR 275,000 cost; break-even needs about 13.7% extra sales. Even the readout's own lift loses money at margin (0.83x). Acceptable variants: rerun as a proper test with randomly assigned (or matched) regions and a holdout before any rollout; stop or pause the programme. A small, controlled re-test counts as PASS.

Naive wrong answer: "The pilot regions grew 11.4 points faster than the company, 2.5x return: roll out to all 18 regions."

PASS if report.md's main recommendation is not to approve the national rollout now (decline, or re-test with a proper control first) and the reasoning includes at least one of: the regression-to-the-mean/untreated-comparison point, the contribution-margin point, or the click & collect inflation.
FAIL if it recommends approving the national rollout (even phased across all regions, or "with tracking") or says the pilot clearly worked.
